{
    "Systemic Therapy for Driver Mutation Negative": {
        "PD-L1 >= 50%": {
            "Pembrolizumab": "Progression (See NSCL-20)",
            "Atezolizumab": "Progression (See NSCL-20)",
            "Cemiplimab": "Progression (See NSCL-20)"
        },
        "PD-L1 1-49%": {
            "Chemotherapy + Immunotherapy": "Progression (See NSCL-20)",
            "Immunotherapy alone (if ineligible for chemo)": "Progression (See NSCL-20)"
        },
        "PD-L1 < 1%": {
            "Chemotherapy + Immunotherapy": "Progression (See NSCL-20)",
            "Chemotherapy": "Progression (See NSCL-20)"
        }
    },
    "footnotes": {
        "1": "See Principles of Systemic Therapy (NSCL-F)."
    }
}